{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:15:57Z","timestamp":1783304157731,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13389-1","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T12:35:12Z","timestamp":1778330112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes in patients with multidrug- or rifampin-resistant tuberculosis treated with bedaquiline and\/or delamanid under the South Korean nationwide approval process"],"prefix":"10.1186","volume":"26","author":[{"given":"Hyeontaek","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Eun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonryu","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Ri","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungseok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongha","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Soo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doosoo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Sun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Joon","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"13389_CR1","unstructured":"Global tuberculosis report 2024 [https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024]."},{"key":"13389_CR2","unstructured":"WHO consolidated guidelines on tuberculosis. Module, 4: treatment - drug-resistant tuberculosis treatment, 2022 update [https:\/\/www.who.int\/publications\/i\/item\/9789240063129]."},{"key":"13389_CR3","unstructured":"Key bottlenecks in M\/XDR-TB control and patient care [https:\/\/www.who.int\/tb\/challenges\/mdr\/bottlenecks\/en\/."},{"issue":"8","key":"13389_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP, de Los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1313865.","journal-title":"N Engl J Med"},{"issue":"23","key":"13389_CR5","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","volume":"366","author":"MT Gler","year":"2012","unstructured":"Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1112433.","journal-title":"N Engl J Med"},{"issue":"9","key":"13389_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","volume":"6","author":"K Schnippel","year":"2018","unstructured":"Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018;6(9):699\u2013706. https:\/\/doi.org\/10.1016\/S2213-26001830235-2.","journal-title":"LancetThe Lancet Respir Med"},{"key":"13389_CR7","unstructured":"WHO consolidated guidelines on drug-resistant tuberculosis treatment [https:\/\/www.who.int\/publications\/i\/item\/9789241550529]."},{"issue":"10","key":"13389_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893\u2013902. https:\/\/doi.org\/10.1056\/NEJMoa1901814.","journal-title":"N Engl J Med"},{"issue":"25","key":"13389_CR9","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"BT Nyang\u2019wa","year":"2022","unstructured":"Nyang\u2019wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-week, all-oral regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387(25):2331\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2117166.","journal-title":"N Engl J Med"},{"issue":"10362","key":"13389_CR10","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","volume":"400","author":"J Mok","year":"2022","unstructured":"Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2\/3 non-inferiority trial in South Korea. Lancet. 2022;400(10362):1522\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(22)01883-9.","journal-title":"Lancet"},{"issue":"10366","key":"13389_CR11","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","volume":"400","author":"RL Goodall","year":"2022","unstructured":"Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet. 2022;400(10366):1858\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(22)02078-5.","journal-title":"Lancet"},{"issue":"9","key":"13389_CR12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S2213-2600(25)00194-8","volume":"13","author":"L Guglielmetti","year":"2025","unstructured":"Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Ali MH, Amjad S, et al. Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. Lancet Respir Med. 2025;13(9):809\u201320. https:\/\/doi.org\/10.1016\/S2213-26002500194-8.","journal-title":"LancetThe Lancet Respir Med"},{"key":"13389_CR13","unstructured":"Korean Guidelines for Tuberculosis [https:\/\/www.kaim.or.kr\/guideline\/index.php?depart=3%26sn=1%26sn2=]."},{"issue":"8","key":"13389_CR14","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/cid\/ciab304","volume":"73","author":"H Hwang","year":"2021","unstructured":"Hwang H, Kang H, Kwon YS, Jeon D, Shim TS, Yim JJ. Outcomes of multidrug-resistant tuberculosis treated with bedaquiline or delamanid. Clin Infect Dis. 2021;73(8):1362\u201369. https:\/\/doi.org\/10.1093\/cid\/ciab304.","journal-title":"Clin Infect Dis"},{"key":"13389_CR15","unstructured":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis. 2016 Update [https:\/\/www.who.int\/publications\/i\/item\/9789241549639]."},{"key":"13389_CR16","unstructured":"WHO consolidated guidelines on tuberculosis. Module, 4: treatment - drug-resistant tuberculosis treatment [https:\/\/www.who.int\/publications\/i\/item\/9789240007048."},{"key":"13389_CR17","unstructured":"Definitions and reporting framework for tuberculosis - 2013 revision: updated. https:\/\/www.who.int\/publications\/i\/item\/9789241505345. December 2014 January 2020."},{"key":"13389_CR18","unstructured":"Guidelines for the control of tuberculosis [https:\/\/tbzero.kdca.go.kr\/tbzero\/main.do."},{"issue":"7","key":"13389_CR19","doi-asserted-by":"publisher","first-page":"850","DOI":"10.5588\/ijtld.18.0658","volume":"23","author":"M Lee","year":"2019","unstructured":"Lee M, Han J, Kim YR, Kwak N, Kim JH, Park O, et al. Multidrug-resistant tuberculosis in South Korea: a retrospective analysis of national registry data in 2011\u20132015. Int J Tuberc Lung Dis. 2019;23(7):850\u201357. https:\/\/doi.org\/10.5588\/ijtld.18.0658.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"13389_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5588\/ijtld.22.0613","volume":"27","author":"ML Rich","year":"2023","unstructured":"Rich ML, Khan U, Zeng C, LaHood A, Franke MF, Atwood S, et al. Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications. Int J Tuberc Lung Dis. 2023;27(6):451\u201357. https:\/\/doi.org\/10.5588\/ijtld.22.0613.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"13389_CR21","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/cid\/ciz1107","volume":"71","author":"RR Kempker","year":"2020","unstructured":"Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline- or delamanid-containing regimens. Clin Infect Dis. 2020;71(9):2336\u201344. https:\/\/doi.org\/10.1093\/cid\/ciz1107.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"13389_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1183\/09031936.00134712","volume":"42","author":"D Falzon","year":"2013","unstructured":"Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42(1):156\u201368. https:\/\/doi.org\/10.1183\/09031936.00134712.","journal-title":"Eur Respir J"},{"key":"13389_CR23","doi-asserted-by":"publisher","unstructured":"Li R, Ma JB, Yang H, Yang H, Yang XJ, Wu YQ, et al. Effects of bedaquiline Combined with Fluoroquinolone and\/or clofazimine on QT interval in patients with Multidrug-Resistant Tuberculosis: a retrospective study. Microbiol. Spectr. 2023;11(4):e0104823. https:\/\/doi.org\/10.1128\/spectrum.01048-23.","DOI":"10.1128\/spectrum.01048-23"},{"issue":"1","key":"13389_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jinf.2021.05.010","volume":"83","author":"LK Dillard","year":"2021","unstructured":"Dillard LK, Martinez RX, Perez LL, Fullerton AM, Chadha S, McMahon CM. Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: a systematic review. J Infect. 2021;83(1):27\u201336. https:\/\/doi.org\/10.1016\/j.jinf.2021.05.010.","journal-title":"J Infect"},{"issue":"2","key":"13389_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.5588\/ijtld.21.0351","volume":"26","author":"E Burhan","year":"2022","unstructured":"Burhan E, Soepandi PZ, Isbaniah F, Damayanti K, Edwar SQ, Maruli MF, et al. Determinants of treatment outcomes in patients with multidrug-resistant TB. Int J Tuberc Lung Dis. 2022;26(2):126\u201332. https:\/\/doi.org\/10.5588\/ijtld.21.0351.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"13389_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41598-023-51026-y","volume":"14","author":"F Wagnew","year":"2024","unstructured":"Wagnew F, Alene KA, Kelly M, Gray D. Impacts of body weight change on treatment outcomes in patients with multidrug-resistant tuberculosis in Northwest Ethiopia. Sci Rep. 2024;14(1):508. https:\/\/doi.org\/10.1038\/s41598-023-51026-y.","journal-title":"Sci Rep"},{"issue":"1","key":"13389_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4046\/trd.2020.0093","volume":"84","author":"Y Kang","year":"2021","unstructured":"Kang Y, Jo EJ, Eom JS, Kim MH, Lee K, Kim KU, et al. Treatment outcomes of patients with multidrug-resistant tuberculosis: comparison of pre- and post-public\u2013private mix periods. Tuberc Respir Dis (Seoul). 2021;84(1):74\u201383. https:\/\/doi.org\/10.4046\/trd.2020.0093.","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"13389_CR28","doi-asserted-by":"publisher","unstructured":"Soeroto AY, Nurhayati RD, Purwiga A, Lestari BW, Pratiwi C, Santoso P, et al. Factors associated with treatment outcome of MDR\/RR-TB patients treated with shorter injectable based regimen in west java Indonesia. PLoS One. 2022;17(1):e0263304. https:\/\/doi.org\/10.1371\/journal.pone.0263304.","DOI":"10.1371\/journal.pone.0263304"},{"issue":"1","key":"13389_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12879-019-4010-7","volume":"19","author":"N Saito","year":"2019","unstructured":"Saito N, Yoshii Y, Kaneko Y, Nakashima A, Horikiri T, Saito Z, et al. Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. BMC Infect Dis. 2019;19(1):374. https:\/\/doi.org\/10.1186\/s12879-019-4010-7.","journal-title":"BMC Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13389-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13389-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13389-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T01:54:08Z","timestamp":1783302848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13389-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13389"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13389-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review board and ethics committee of Seoul National University Hospital (IRB No. E-2408-102-1562). The study adhered to the ethical principles outlined in the Declaration of Helsinki. The requirement for informed consent was waived by the institutional review board and ethics committee of Seoul National University Hospital following review of a waiver request submitted by the investigators.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Yim received donations of linezolid (Zyvox) from Pfizer Inc. and delamanid (Deltyba) from Otsuka Pharmaceutical Co. for the clinical trials which he served as a principal investigator. Dr Shim reports receiving a research grant for the present study from the Korea Disease Control and Prevention Agency (grant number 20240408124-00).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1231"}}